Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as C$0.01 and last traded at C$0.01, with a volume of 90651 shares. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Stock Performance
The company has a debt-to-equity ratio of 138.88, a quick ratio of 0.46 and a current ratio of 0.07. The firm has a market capitalization of C$663,150.00, a PE ratio of -0.50 and a beta of -0.02. The firm’s 50 day moving average price is C$0.01 and its 200-day moving average price is C$0.01.
Aequus Pharmaceuticals Company Profile
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Featured Stories
- Five stocks we like better than Aequus Pharmaceuticals
- What is the Dogs of the Dow Strategy? Overview and Examples
- SAP’s Strong Momentum: A Bullish Setup for Investors
- Which Wall Street Analysts are the Most Accurate?
- BlackRock Breaks Records: Why the Stock Still Has Room to Run
- Where to Find Earnings Call Transcripts
- Duke vs. NRG: Which Energy Stock Will Power Higher Gains?
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
